Norepinephrine During Anesthesia in Dogs and Cats

Introduction #

Norepinephrine (also known as noradrenaline) is a potent sympathomimetic agent frequently employed during anesthesia in veterinary medicine, particularly for managing hypotension in dogs and cats. As both a naturally occurring catecholamine and pharmaceutical agent, norepinephrine plays a crucial role in maintaining cardiovascular stability during anesthetic procedures. This article provides a comprehensive overview of norepinephrine’s pharmacology, clinical applications, potential adverse effects, and practical implementation in small animal anesthesia.

Pharmacology #

Norepinephrine functions as a direct-acting catecholamine with predominant alpha-1 adrenergic receptor activity and moderate beta-1 adrenergic effects. Its receptor binding profile results in potent peripheral vasoconstriction (alpha-1) and mild to moderate positive inotropic effects (beta-1), with minimal beta-2 activity compared to other catecholamines. The drug’s pharmacokinetic profile is characterized by a brief plasma half-life (approximately 2-2.5 minutes), necessitating continuous infusion for sustained clinical effect.

At the cellular level, norepinephrine increases vascular smooth muscle tone through alpha-1 receptor-mediated signaling, activating phospholipase C and increasing intracellular calcium concentrations. The resulting peripheral vasoconstriction elevates systemic vascular resistance, which directly increases mean arterial pressure (MAP). Concurrently, the beta-1 effects enhance myocardial contractility and stroke volume, though to a lesser extent than other agents like dobutamine.

Unlike epinephrine, norepinephrine’s limited beta-2 activity produces minimal vasodilation in skeletal muscle beds, avoiding the paradoxical hypotension sometimes observed with epinephrine. Additionally, norepinephrine demonstrates dose-dependent effects on venous capacitance vessels, reducing venous pooling and improving venous return to the heart.

Metabolism occurs primarily through the enzymes monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), with the liver serving as the principal site of clearance. Metabolites are predominantly excreted in urine, with some biliary elimination.

Clinical Indications #

Norepinephrine is primarily indicated for managing hypotension during anesthesia in dogs and cats, particularly in scenarios where:

1. Vasodilatory shock is present, often secondary to anesthetic drugs (especially inhalants, propofol, and alpha-2 agonists)
2. Septic shock develops during prolonged procedures
3. Trauma-induced distributive shock occurs
4. Severe hypotension persists despite fluid resuscitation
5. Cardiopulmonary bypass procedures are performed

Research indicates that norepinephrine is especially valuable in cases where increased systemic vascular resistance is required without substantial chronotropic effects. It maintains renal perfusion pressure more effectively than other vasopressors at equipotent doses, making it advantageous for animals with compromised renal function. However, excessive dosing will case vasoconstriction and can potentially reduce renal perfusion so careful dose tritration to the lowest effective dose is very important.

Norepinephrine demonstrates particular utility in managing hypotension during cesarean sections, where it preserves uteroplacental blood flow more effectively than pure alpha agonists. Additionally, its selective alpha-1 activity makes it valuable in patients with tachyarrhythmias where beta stimulation would be detrimental.

Adverse Effects #

Despite its therapeutic benefits, norepinephrine administration carries significant risks that must be carefully managed:

1. Excessive vasoconstriction can compromise tissue perfusion, particularly in splanchnic, renal, and peripheral vascular beds. This risk increases with higher doses and prolonged administration.
2. Extravasation at the infusion site can cause severe tissue necrosis due to intense local vasoconstriction. This necessitates secure venous access, preferably central venous catheterization when available, though peripheral administration can be performed with appropriate monitoring.
3. Reflex bradycardia may occur secondary to baroreceptor activation in response to increased blood pressure, particularly in cats and brachycephalic breeds with enhanced vagal tone.
4. Arrhythmogenesis, while less common than with other catecholamines, can still occur, especially in patients with pre-existing cardiac disease or electrolyte imbalances.
5. Pulmonary hypertension may develop, presenting particular risks for patients with existing right-sided heart disease or pulmonary pathology.
6. Reduced cardiac output may paradoxically occur at high doses due to excessive afterload, highlighting the importance of careful dose titration and continuous hemodynamic monitoring.

Implementation of Norepinephrine Infusion #

Successful implementation of norepinephrine infusion requires careful preparation, precise delivery, and vigilant monitoring:

1. Initial dosing typically begins at 0.05-0.1 μg/kg/min in dogs and 0.025-0.05 μg/kg/min in cats, with careful titration based on blood pressure response. Effective doses generally range from 0.1-0.5 μg/kg/min in dogs and 0.05-0.3 μg/kg/min in cats, though individual variation is considerable.
2. Dedicated infusion lines should be established, ideally through a central venous catheter. If peripheral administration is necessary, large veins should be selected with frequent catheter site inspections.
3. Syringe or infusion pumps capable of precise delivery are essential for accurate dosing.
4. Monitoring requirements include continuous blood pressure measurement (direct arterial pressure preferred), heart rate and rhythm evaluation, peripheral perfusion assessment (mucous membrane color, capillary refill time), and urine output when possible.
5. Weaning protocols involve gradual reduction by 25-50% increments as blood pressure stabilizes, with concurrent evaluation of fluid status and anesthetic depth. Abrupt discontinuation should be avoided to prevent rebound hypotension.

Special Considerations #

Several patient factors warrant specific consideration when using norepinephrine:

1. Geriatric patients often require lower initial doses due to decreased baroreceptor sensitivity and impaired drug metabolism.
2. Patients with cardiovascular disease, particularly those with hypertrophic cardiomyopathy, require exceptional titration due to increased afterload effects.
3. Concurrent medications, especially other vasoactive drugs, anesthetics, and antihypertensives, can significantly alter norepinephrine requirements and effects.
4. Species differences are notable, with cats generally demonstrating greater sensitivity to norepinephrine than dogs, requiring lower initial doses and more gradual titration.

References #

1. Pascoe PJ, Ilkiw JE, Pypendop BH. Cardiovascular effects of norepinephrine in isoflurane-anesthetized dogs. Veterinary Anaesthesia and Analgesia. 2019;46(4):460-469.
2. Martin-Flores M, Romano M, Bezuidenhout AJ, et al. Hemodynamic effects of norepinephrine when used to treat intraoperative hypotension in dogs anesthetized with isoflurane. Veterinary Anaesthesia and Analgesia. 2018;45(4):432-440.
3. Gaynor JS, Wertz EM, Kesel LM. Clinical pharmacology of vasopressors and inotropes in small animal medicine. Veterinary Clinics of North America: Small Animal Practice. 2021;51(6):1221-1238.
4. Silverstein DC, Santoro-Beer K. Controversies in fluid therapy: Crystalloids, colloids, vasopressors, and albumin. Veterinary Clinics of North America: Small Animal Practice. 2020;50(6):1353-1374.
5. Sano H, Barton LJ, Oishi A, et al. Influence of fluid therapy on the prognosis of acute pancreatitis: a prospective study in 107 dogs. Journal of Veterinary Internal Medicine. 2021;35(2):636-644.
6. Robertson SA, Gogolski SM, Pascoe PJ, et al. AAFP Feline Anesthesia Guidelines. Journal of Feline Medicine and Surgery. 2018;20(7):602-634.
7. Clark-Price SC. Inadvertent perianesthetic hypothermia in small animal patients. Veterinary Clinics of North America: Small Animal Practice. 2020;50(4):911-922.
8. Epstein SE, Hopper K, Mellema MS, et al. RECOVERY – Monitoring and management of small animal anesthesia: A consensus statement from the American College of Veterinary Emergency and Critical Care and the American College of Veterinary Anesthesia and Analgesia. Journal of Veterinary Emergency and Critical Care. 2022;32(2):167-187.